FY2025 · ended Dec 31, 2025 · Revenue $255.87M, +23.3% YoY · Filed Feb 25, 2026
Schrodinger, Inc. (SDGR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $255.9 million and a net loss of $103.3 million. Free cash flow was $12.5 million. As of Sep 30, 2026 it held $366.4 million in cash and investments and $104.6 million in total debt.
Revenue (TTM)
$269.20M
+4.8% vs year-ago TTM
Net income (TTM)
$-59.25M
+66.3% vs year-ago TTM
Operating cash flow (TTM)
$-112.58M
-9942.4% vs year-ago TTM
Free cash flow (TTM)
$-116.77M
-3339.6% vs year-ago TTM
EPS (TTM)
$-0.80
+66.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
62.98M
+1.3% vs prior year
Net cash
$261.73M
as of Sep 30, 2026
Operating margin
-49.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SDGR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1490978
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $255.9M | $207.5M | $216.7M | $181.0M | $137.9M |
| Operating income | -$166.9M | -$209.3M | -$177.4M | -$146.8M | -$111.4M |
| Net income | -$103.3M | -$187.1M | $40.7M | -$149.2M | -$100.4M |
| Diluted EPS | -$1.41 | -$2.57 | $0.54 | -$2.10 | — |
| Operating cash flow | $13.9M | -$157.4M | -$136.7M | -$119.7M | -$70.7M |
| Free cash flow | $12.5M | -$164.7M | -$150.1M | -$127.7M | -$77.8M |
| Total assets | $726.2M | $823.2M | $803.0M | $688.6M | $756.5M |
| Total liabilities | $362.1M | $401.8M | $254.4M | $240.7M | $199.4M |
| Stockholders' equity | $364.1M | $421.4M | $548.6M | $447.9M | $557.1M |
| Cash and investments | $395.5M | $352.1M | $463.0M | $451.1M | $576.5M |
| Total debt | $109.2M | $117.8M | $127.9M | $116.5M | $79.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 29, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 23, 2026 | Jun 22, 2026 |
All 539 Schrodinger, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.